Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.

Susanne Gahr; Till Wissniowski; Steffen Zopf; Deike Strobel; Anette Pustowka; Matthias Ocker

doi:10.7150/jca.4211

Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.

Susanne Gahr (First author)
, Till Wissniowski
, Steffen Zopf
, Deike Strobel
, Anette Pustowka
, Matthias Ocker

Department of Internal Medicine III, Division of Respiratory Medicine, Allergology and Sleep Medicine

Research output: Contribution to journal › Original Article › peer-review

21 Citations (Web of Science)

Original language	English
Pages (from-to)	158-165
Journal	JOURNAL OF CANCER
Volume	3
DOIs	https://doi.org/10.7150/jca.4211
Publication status	Published - 2012

Keywords

GASTROINTESTINAL TUMOR-CELLS
HISTONE-DEACETYLASE
CANCER-CELLS
RAF/MEK/ERK PATHWAY
TARGETED THERAPIES
ANTITUMOR-ACTIVITY
CD95 ACTIVATION
HEPATOMA-CELLS
ANGIOGENESIS
VORINOSTAT

Access to Document

10.7150/jca.4211

Cite this

Gahr, S., Wissniowski, T., Zopf, S., Strobel, D., Pustowka, A., & Ocker, M. (2012). Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. JOURNAL OF CANCER, 3, 158-165. https://doi.org/10.7150/jca.4211

@article{62d9270c5d5a4be0875ef7156b2a8324,

title = "Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.",

keywords = "GASTROINTESTINAL TUMOR-CELLS, HISTONE-DEACETYLASE, CANCER-CELLS, RAF/MEK/ERK PATHWAY, TARGETED THERAPIES, ANTITUMOR-ACTIVITY, CD95 ACTIVATION, HEPATOMA-CELLS, ANGIOGENESIS, VORINOSTAT",

author = "Susanne Gahr and Till Wissniowski and Steffen Zopf and Deike Strobel and Anette Pustowka and Matthias Ocker",

note = "Gahr: Klinikum Nuremberg Nord, Department of Pneumology, Nuremberg, Germany",

year = "2012",

doi = "10.7150/jca.4211",

language = "English",

volume = "3",

pages = "158--165",

journal = "JOURNAL OF CANCER",

issn = "1837-9664",

publisher = "Ivyspring Int Publ",

}

Gahr, S, Wissniowski, T, Zopf, S, Strobel, D, Pustowka, A & Ocker, M 2012, 'Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.', JOURNAL OF CANCER, vol. 3, pp. 158-165. https://doi.org/10.7150/jca.4211

Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. / Gahr, Susanne (First author); Wissniowski, Till; Zopf, Steffen et al.
In: JOURNAL OF CANCER, Vol. 3, 2012, p. 158-165.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.

AU - Gahr, Susanne

AU - Wissniowski, Till

AU - Zopf, Steffen

AU - Strobel, Deike

AU - Pustowka, Anette

AU - Ocker, Matthias

N1 - Gahr: Klinikum Nuremberg Nord, Department of Pneumology, Nuremberg, Germany

PY - 2012

Y1 - 2012

KW - GASTROINTESTINAL TUMOR-CELLS

KW - HISTONE-DEACETYLASE

KW - CANCER-CELLS

KW - RAF/MEK/ERK PATHWAY

KW - TARGETED THERAPIES

KW - ANTITUMOR-ACTIVITY

KW - CD95 ACTIVATION

KW - HEPATOMA-CELLS

KW - ANGIOGENESIS

KW - VORINOSTAT

U2 - 10.7150/jca.4211

DO - 10.7150/jca.4211

M3 - Original Article

C2 - 22514558

SN - 1837-9664

VL - 3

SP - 158

EP - 165

JO - JOURNAL OF CANCER

JF - JOURNAL OF CANCER

ER -